Search

Objective: The widespread distribution of the vitamin D receptor across various tissues has expanded the understanding of vitamin D beyond its traditional role in calcium and bone metabolism. Severe vitamin D deficiency not only affects bone health but also impacts various aspects of the musculoskeletal system. This study aims to investigate the immediate postoperative benefits of high-dose vitamin D administration for hip fracture patients. Methods: This study enrolled 85 consecutive patients aged over 60 years with hip fractures at our university hospital between 2013 and 2014. Patients were divided into 2 groups based on fracture location: pertrochanteric fractures in the osteosynthesis group and femoral neck fractures in the arthroplasty group. Each group was further divided based on preoperative vitamin D administration. Perioperative surgical parameters, length of hospital stay, early postoperative physical performance, and occurrence of delirium were recorded. Results: The study included 85 participants undergoing bipolar hemiarthroplasty (n = 34) and proximal femoral nail (n = 51) procedures. No significant differences were observed in delirium incidence, operation duration, bleeding, or perioperative blood pressure between groups. Hemiarthroplasty patients receiving vitamin D showed improved 8-foot up and go test performance, while the proximal femoral nail group had shorter hospital stays. Delirium correlated with age and polypharmacy; however, the incidence of delirium was not influenced by vitamin D supplementation. Conclusion: High-dose vitamin D supplementation significantly reduced hospital stays for osteoporotic proximal femur fractures treated with osteosynthesis using a proximal femoral nail. Vitamin D replacement also improved short-term physical performance in patients with femoral neck fractures treated with hemiarthroplasty. Vitamin D supplementation offers a safe and cost-effective adjunct therapy for the recovery of elderly patients from hip fractures.

Objective: The aim of this study was to determine factors associated with the likelihood of a better clinical outcome after the peritendinous injection of PRP for the treatment of chronic tendinopathy and identify whether PRP represents an effective treatment option for chronic tendinopathies. Methods: The study included 214 patients (86 males and 128 females; mean age: 39.3 (18–75) years) who received PRP injections for tendinopathy refractory to conventional treatments. The mean duration of symptoms at the moment of the PRP treatment was 8.3 months. Primary outcome measurement was perceived improvement in symptoms for each anatomic compartment for upper and lower limbs at 6 months after treatment. Also, a visual analog scale (VAS) score (pain intensity on a 0–10 scale) was used for pain scoring questionnaire before treatment, 6 weeks and 6 months following the PRP injection(s). To identify factors associated with the likelihood of a better clinical outcome, patients were categorized on the basis of their perceived improvement in symptoms 6 months after the PRP injection(s)—that is, as lower (less than 50% global improvement) or higher (more than 50% global improvement). Results: A visual analogue scale score and perceived improvement in symptoms were significantly lower after peritendinous injection in 6-week and 6-month follow-ups compared with the baseline (P 50%) in pain symptoms was observed in most of the patients. Our research found that results were most promising with patellar and lateral epicondylar tendinopathy in the short to medium term. Female patients, patients with upper extremity tendinopathy and older patients appeared to benefit more from PRP injection. Level of evidence: Level IV, Therapeutic study. Keywords: Platelet-rich plasma, Tendinopathy, Injection, Achilles tendon, Patellar tendon, Lateral epicondylitis